Exenatide
AGREE
AstraZeneca · Phase 2/3 · Status n/r · Enrollment 28
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Exenatide | Obesity or overweight | n/r | 4 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 4 | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Exenatide
AstraZeneca · Phase 2/3 · Status n/r · Enrollment 28
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Exenatide | Obesity or overweight | n/r | 4 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 4 | n/r | n/r |